The Bob Harrington ShowView all posts »
#42: Statins--Cardiovascular benefit vs diabetes risk with Dr Michael CobbleNov 1, 2011 10:35 EDT
Statins have become a cornerstone therapy in the prevention of cardiovascular disease by helping to modify the risk profile of millions of people. But what about a possible connection between statin use and diabetes? Lipidologist and preventive expert Dr Michael Cobble joins the show to relate his examination of the data and clinical experience and share his thoughts on the advantages of statin use relative to the risk of diabetes.
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statins trials. Lancet 2010; 375:735-742. Available here.
Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA 2011; 305:2556-2564. Available here.
Dr Cobble has served as an advisor or consultant for Abbott, AstraZeneca, and Bristol Myers-Squibb. He has served as a speaker of member of a speaker's bureau for Abbott, AstraZeneca, Bristol Myers-Squibb, Eli Lilly, Boehringer Ingelheim, Novo, and Forest. Dr Cobble is employed by Atherotech Cardiometabolic Diagnostic Lab and runs a private practice, Canyons Medical Center.
For Dr Harrington's disclosures, click here.